Bambusa Therapeutics key facts
as of Oct 2026- Operator of a biotechnology company intended to create bispecific antibodies for treating immunological and inflammatory disorders.
- Bambusa Therapeutics is valued at approximately $555.0M as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $143.0M across 4 recorded rounds; the latest was Early Stage VC (Series A2) ($40.0M) in Oct 2025.
- Notable investors include RA Capital Management, The Invus Group, INCE Capital, Redmile Group, Salvia (Holzkirchen) — 11 tracked in total.
- Bambusa Therapeutics has filed 3 Form Ds with the SEC, most recently Feb 2025 ($53.3M sold to 16 investors).
- Status: Privately Held (backing).
Valued at $555.0M at its early-stage round, Oct 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch Bambusa Therapeutics: the Monday email on marks, rounds and moves
Bambusa Therapeutics funding rounds
4 roundsWho backs Bambusa Therapeutics
11+Bambusa Therapeutics valuation
Bambusa Therapeutics was valued at $555 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Bambusa Therapeutics raised?
Bambusa Therapeutics has raised $143 million across 4 recorded rounds since 2024. The largest was a $9 million early-stage round in Jun 2024; the most recent was a $40 million Series A2 in Oct 2025.
Bambusa Therapeutics has filed 3 Form Ds with the SEC, most recently in Feb 2025 ($53.3 million sold to 16 investors).
Bambusa Therapeutics investors
11 investors are on record for Bambusa Therapeutics, including RA Capital Management, The Invus Group, INCE Capital and Redmile Group. The Series A2 in Oct 2025 drew 9 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: VeraDermics (NYS: MANE) ($596 million), Superluminal Medicines ($576 million) and Strand Therapeutics ($571 million).
About Bambusa Therapeutics
Operator of a biotechnology company intended to create bispecific antibodies for treating immunological and inflammatory disorders. The company specializes in building a diverse portfolio of molecules and using antibody development capabilities to provide targeted therapies, enabling the healthcare industry to treat patients suffering from debilitating and chronic inflammatory conditions.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Employees
- 12
- Website
- bambusatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.